Literature DB >> 20408844

Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms.

Savita Bhalla, Leo I Gordon, Kevin David, Sheila Prachand, Amareshwar T K Singh, Shuo Yang, Jane N Winter, Dongsheng Guo, Thomas O'Halloran, Leonidas C Platanias, Andrew M Evens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20408844      PMCID： PMC2910124          DOI： 10.1111/j.1365-2141.2010.08197.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  13 in total

1.  Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.

Authors:  J Dai; R S Weinberg; S Waxman; Y Jing
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

2.  Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

Authors:  Joya Chandra; Jeannette Tracy; David Loegering; Karen Flatten; Srdan Verstovsek; Miloslav Beran; Mercedes Gorre; Zeev Estrov; Nicholas Donato; Moshe Talpaz; Charles Sawyers; Kapil Bhalla; Judith Karp; Edward Sausville; Scott H Kaufmann
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

3.  The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide.

Authors:  J Yi; F Gao; G Shi; H Li; Z Wang; X Shi; X Tang
Journal:  Apoptosis       Date:  2002-06       Impact factor: 4.677

4.  Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway.

Authors:  Y Jing; J Dai; R M Chalmers-Redman; W G Tatton; S Waxman
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

5.  Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state.

Authors:  Ronald B Gartenhaus; Sheila N Prachand; Mary Paniaqua; Yuyu Li; Leo I Gordon
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

Review 6.  Mechanisms of action of arsenic trioxide.

Authors:  Wilson H Miller; Hyman M Schipper; Janet S Lee; Jack Singer; Samuel Waxman
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells.

Authors:  Andrew M Evens; Philip Lecane; Darren Magda; Sheila Prachand; Seema Singhal; Jeff Nelson; Richard A Miller; Ronald B Gartenhaus; Leo I Gordon
Journal:  Blood       Date:  2004-09-23       Impact factor: 22.113

Review 8.  The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.

Authors:  Andrew M Evens; Martin S Tallman; Ronald B Gartenhaus
Journal:  Leuk Res       Date:  2004-09       Impact factor: 3.156

9.  Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.

Authors:  K Davison; S Côté; S Mader; W H Miller
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

10.  A phase I clinical trial of darinaparsin in patients with refractory solid tumors.

Authors:  Apostolia Maria Tsimberidou; Luis H Camacho; Srdan Verstovsek; Chaan Ng; David S Hong; Cynthia K Uehara; Catalina Gutierrez; Shawn Daring; Jan Stevens; Philip B Komarnitsky; Brian Schwartz; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531
View more
  6 in total

1.  Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Authors:  Paul M Barr; Thomas P Miller; Jonathan W Friedberg; Derick R Peterson; Andrea M Baran; Megan Herr; Catherine M Spier; Haiyan Cui; Denise J Roe; Daniel O Persky; Carla Casulo; Jamie Littleton; Mark Schwartz; Soham Puvvada; Terry H Landowski; Lisa M Rimsza; Robert T Dorr; Richard I Fisher; Steven H Bernstein; Margaret M Briehl
Journal:  Blood       Date:  2014-07-11       Impact factor: 22.113

2.  Effects of arsenic sulfide (As2S2) on B and T lymphoma cell lines and possible underlying mechanisms.

Authors:  Xianglu Li; Xinyu Liu; Ling Wang; Xiao Lv; Peipei Li; Kang Lu; Xin Wang
Journal:  Biomed Rep       Date:  2013-05-30

3.  Nephroprotective effect of astaxanthin against trivalent inorganic arsenic-induced renal injury in wistar rats.

Authors:  Xiaona Wang; Haiyuan Zhao; Yilan Shao; Pei Wang; Yanru Wei; Weiqian Zhang; Jing Jiang; Yan Chen; Zhigang Zhang
Journal:  Nutr Res Pract       Date:  2014-01-29       Impact factor: 1.926

Review 4.  ROS homeostasis and metabolism: a dangerous liason in cancer cells.

Authors:  E Panieri; M M Santoro
Journal:  Cell Death Dis       Date:  2016-06-09       Impact factor: 8.469

5.  Pyrrolidine Dithiocarbamate Facilitates Arsenic Trioxide Against Pancreatic Cancer via Perturbing Ubiquitin-Proteasome Pathway.

Authors:  Simin Yu; Ning Wu; Jianmin Zhu; Ying Liu; Jinbin Han
Journal:  Cancer Manag Res       Date:  2020-12-22       Impact factor: 3.989

6.  Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo.

Authors:  Richard W Ahn; Susan L Barrett; Meera R Raja; Jennifer K Jozefik; Lidia Spaho; Haimei Chen; Marcel B Bally; Andrew P Mazar; Michael J Avram; Jane N Winter; Leo I Gordon; Lonnie D Shea; Thomas V O'Halloran; Teresa K Woodruff
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.